In the pooled cohort, 283 patients with advanced NSCLC and PD-L1 expression ≥50% were treated with cemiplimab monotherapy, and 312 patients with advanced NSCLC and no EGFR, ALK, or ROS1 genomic aberrations were treated with cemiplimab plus chemotherapy (9, 10). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.